RxDoctor Payments DataLook up a doctor →

Nitesh Gadeela, MD

Interventional Cardiology · Indianapolis, INNPI 1962525790

Payments from drug & device makers

$48,331in general payments, 2019–2025

Across 560 payments — averaging $86.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • Johnson & Johnson$8K
  • Penumbra, Inc.$6K
  • Heartflow, Inc.$3K
  • Cardiovascular Systems Inc.$3K
  • Abiomed$661
  • plus $7K from 40 others

What the payments were for

  • Speaking & faculty fees$5,60012%
  • Travel & lodging$16,04833%
  • Food & beverage$26,67255%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,331 in reported general payments places this provider in the 85th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$225,231
Medicare patients
1,374
Services billed
2,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$179,734
EntrestoSacubitril/Valsartan83$113,771
XareltoRivaroxaban49$74,946
BrilintaTicagrelor46$49,692
Repatha SureclickEvolocumab20$27,540
JardianceEmpagliflozin32$27,054
Praluent PenAlirocumab19$23,902
FarxigaDapagliflozin Propanediol13$16,074
Prasugrel Hcl67$9,542
ClopidogrelClopidogrel Bisulfate682$6,944
Metoprolol Succinate604$5,698
VascepaIcosapent Ethyl12$4,980
Ranolazine ErRanolazine51$4,427
Atorvastatin Calcium505$3,976
Diltiazem 24hr Er (La)Diltiazem Hcl13$2,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$642$179,734152 claims
NovartisEntresto$518$113,77183 claims
Johnson & JohnsonXarelto$7,874$74,94649 claims
AstraZenecaBrilinta, Farxiga$537$65,76659 claims
Boehringer IngelheimJardiance$139$27,05432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →